EFFECT OF LYMPHOBLASTOID ALFA-INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS-C HAVING DIFFERENT GENOTYPIC SUBTYPE OF HEPATITIS-C VIRUS

被引:8
作者
CHAYAMA, K
TSUBOTA, A
ARASE, Y
SAITOH, S
IKEDA, K
MATSUMOTO, T
SAKAI, Y
KOBAYASHI, M
MORINAGA, T
KUMADA, H
机构
[1] Department of Gastroenterology and Liver Research Laboratory Toranomon Hospital, Tokyo
[2] Department of Molecular Biology, TEIJIN Ltd, Hino
来源
GASTROENTEROLOGIA JAPONICA | 1993年 / 28卷
关键词
D O I
10.1007/BF02989204
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Five subtypes of hepatitis C virus (Pt[I], K1[II], K2a[III], K2b[IV] and Tr[V]) have been suggested based on the nucleotide sequence of the non-structural five region. To assess the susceptibility of each subtype to interferon therapy, we developed a one-step method which allows quick determination of subtype using polymerase chain reaction with a mixed primer set deduced from the sequence of each subtype. We were able to determine the subtype of 69 of 80 (86.3%) Japanese patients who received natural alfa-interferon treatment. The incidence of each subtype was K1: 53 (76.8%), K2a: 14 (20.3%), K2b: 3 (4.3%) and Tr: 1 (1.4%). Interferon was administered to these patients and found to be effective in 28 of 51 (54.9%) patients with K1 subtype and in 16 of 18 (88.9%) patients with other subtypes (P< 0.01). These data show that K1 is a major subtype in Japan and relatively resistant to interferon treatment. © 1993 The Japanese Society of Gastroenterology.
引用
收藏
页码:45 / 47
页数:3
相关论文
共 50 条
[41]   PRETREATMENT SERUM HEPATITIS-C VIRUS-RNA LEVELS AND HEPATITIS-C VIRUS GENOTYPE ARE THE MAIN AND INDEPENDENT PROGNOSTIC FACTORS OF SUSTAINED RESPONSE TO INTERFERON-ALFA THERAPY IN CHRONIC HEPATITIS-C [J].
MARTINOTPEIGNOUX, M ;
MARCELLIN, P ;
POUTEAU, M ;
CASTELNAU, C ;
BOYER, N ;
POLIQUIN, M ;
DEGOTT, C ;
DESCOMBES, I ;
LEBRETON, V ;
MILOTOVA, V ;
BENHAMOU, JP ;
ERLINGER, S .
HEPATOLOGY, 1995, 22 (04) :1050-1056
[42]   HEPATITIS-C VIRUS-RNA RESPONSE TO INTERFERON-ALPHA THERAPY OF CHRONIC HEPATITIS-C [J].
ZAFAR, M ;
ELLIS, M ;
SIECK, JO ;
ALFURAYH, O ;
ALI, A ;
AYUB, A ;
ALFADDA, M .
GASTROENTEROLOGY, 1993, 104 (04) :A1023-A1023
[43]   ANTIVIRAL EFFECT OF RECOMBINANT INTERFERON-ALFA-2A ON HEPATITIS-C VIRUS [J].
YOKOSUKA, O ;
OMATA, M ;
HOSODA, K ;
KATO, N ;
OHTO, M .
INTERNATIONAL HEPATOLOGY COMMUNICATIONS, 1993, 1 (03) :128-132
[44]   IMMUNOGLOBULIN-M ANTIBODY TO HEPATITIS-C VIRUS DURING INTERFERON THERAPY FOR CHRONIC HEPATITIS-C [J].
QUIROGA, JA ;
BOSCH, O ;
GONZALEZ, R ;
MARRIOTT, E ;
CASTILLO, I ;
BARTOLOME, J ;
CARRENO, V .
GASTROENTEROLOGY, 1992, 103 (04) :1285-1289
[45]   PREDICTIVE VALUE OF HEPATITIS-C VIRUS DENSITY ANALYSIS FOR RELAPSE IN INTERFERON-TREATED CHRONIC HEPATITIS-C PATIENTS [J].
KANTO, T ;
HAYASHI, N ;
TAKEHARA, T ;
HAGIWARA, H ;
MITA, E ;
KASAHARA, A ;
FUSAMOTO, H ;
KAMADA, T .
HEPATOLOGY, 1994, 20 (04) :A157-A157
[46]   DETECTION OF HEPATITIS-C VIRUS-RNA IN SERUM OF PATIENTS WITH CHRONIC HEPATITIS-C TREATED WITH INTERFERON-ALPHA [J].
HAGIWARA, H ;
HAYASHI, N ;
MITA, E ;
UEDA, K ;
TAKEHARA, T ;
KASAHARA, A ;
FUSAMOTO, H ;
KAMADA, T .
HEPATOLOGY, 1992, 15 (01) :37-41
[47]   CHANGES OF SERUM HEPATITIS-C VIRUS LEVELS IN PATIENTS WITH CHRONIC HEPATITIS-C TREATED WITH 2 COURSES OF INTERFERON ADMINISTRATION [J].
SAITOH, Y ;
MIURA, M ;
NIITSUMA, H ;
NUMATA, N ;
HITOSHI, O ;
ISHII, M ;
TOYOTA, T .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 173 (04) :361-369
[48]   RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT INTERFERON ALFA IN PATIENTS WITH CHRONIC HEPATITIS-C [J].
COLOMBO, M ;
RUMI, MG ;
MARCELLI, R ;
IBBA, M ;
PARRAVICINI, ML ;
DONATO, MF ;
DELNINNO, E .
HEPATOLOGY, 1991, 14 (04) :A73-A73
[49]   NATURAL ALFA-INTERFERON (N-ALPHA-IFN) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS-C NONRESPONDERS TO RECOMBINANT ALFA-INTERFERON (R-ALPHA-IFN) [J].
PICCIOTTO, A ;
BARDELLINI, E ;
BORRO, P ;
PIREDDU, M ;
SINELLI, N ;
CELLE, G .
GASTROENTEROLOGY, 1995, 108 (04) :A1147-A1147
[50]   ANTIVIRAL EFFECT OF INTERFERON THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS-C [J].
HAYASHI, J ;
NAKASHIMA, K ;
NOGUCHI, A ;
HIRATA, M ;
AKAZAWA, K ;
KASHIWAGI, S .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1992, 3 (05) :305-309